- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Beltsville Today
By the People, for the People
NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
The antibody drug conjugate is being evaluated for advanced solid tumors, including platinum resistant ovarian cancer.
Mar. 31, 2026 at 10:00pm
Got story updates? Submit your updates here. ›
NextCure, Inc. and Simcere Zaiming Pharmaceutical Co., Ltd. announced that an abstract for their investigational antibody drug conjugate (ADC) SIM0505, which targets Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor payload, has been accepted for presentation at the American Society for Clinical Oncology (ASCO) 2026 meeting. SIM0505 is currently being evaluated in an ongoing open-label, Phase 1 study for the potential treatment of advanced solid tumors, with a focus on platinum resistant ovarian cancer.
Why it matters
The acceptance of the SIM0505 abstract for ASCO 2026 represents an important milestone in the development of this novel ADC, which has the potential to address the significant unmet need for effective treatments for advanced solid tumors, particularly platinum resistant ovarian cancer. The presentation at the prestigious ASCO meeting will provide an opportunity to share the latest data and insights on SIM0505 with the broader oncology community.
The details
SIM0505 is a novel antibody drug conjugate (ADC) directed to cadherin-6 (CDH6), featuring a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ADC is designed for broad anti-tumor activity, fast systemic clearance, and an improved potential therapeutic window. The ongoing open-label, Phase 1 study (NCT06792552) is evaluating SIM0505 in advanced solid tumors, including ovarian cancer, with an emphasis on platinum resistant ovarian cancer.
- The ASCO 2026 meeting will be held from May 29 to June 2, 2026 in Chicago, Illinois.
- The ongoing Phase 1 study of SIM0505 (NCT06792552) is currently underway.
The players
NextCure, Inc.
A clinical-stage biopharmaceutical company focused on advancing innovative medicines to treat cancer patients through the use of targeted therapies including antibody-drug conjugates.
Simcere Zaiming Pharmaceutical Co., Ltd.
An oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited, dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally.
SIM0505
An investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload, currently being evaluated in a Phase 1 study for the potential treatment of advanced solid tumors, including ovarian cancer.
What’s next
The ongoing Phase 1 study of SIM0505 (NCT06792552) will continue to evaluate the safety and efficacy of the investigational ADC in patients with advanced solid tumors, including ovarian cancer, with a focus on platinum resistant disease.
The takeaway
The development of SIM0505, a novel ADC targeting CDH6, represents a promising approach to addressing the significant unmet need for effective treatments for advanced solid tumors, particularly platinum resistant ovarian cancer. The acceptance of the abstract for ASCO 2026 will provide an opportunity to share the latest data and insights on this investigational therapy with the broader oncology community.
